Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 11/20 | 0.81 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.81 |
| ▸ | CDK8 | P49336 | 4/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15915977 | 0.90 | ALOX5AP (1.00) | FEN1ALOX5AP | |
| SCHEMBL1487537 | 0.85 | FEN1 (0.61) | FEN1ALOX5APCDK8AXLNUDT1 | |
| SCHEMBL13854146 | 0.81 | CDK8 (0.57) | FEN1ALOX5APCDK8AXLNUDT1 | |
| SCHEMBL15916648 | 0.80 | ALOX5AP (1.00) | FEN1ALOX5AP | |
| SCHEMBL3348956 | 0.77 | AXL (0.56) | FEN1ALOX5APCDK8AXLNUDT1 | |
| SCHEMBL8320112 | 0.76 | ALOX5AP (0.52) | FEN1ALOX5APCDK8AXL | |
| SCHEMBL15730259 | 0.75 | FEN1 (0.57) | FEN1ALOX5APCDK8AXLNUDT1 | |
| SCHEMBL3348251 | 0.75 | CDK8 (0.56) | FEN1ALOX5APCDK8AXLNUDT1 | |
| SCHEMBL858203 | 0.75 | CDK8 (0.64) | FEN1ALOX5APCDK8AXLNUDT1 | |
| SCHEMBL31064990 | 0.75 | CDK8 (0.64) | FEN1ALOX5APCDK8AXLNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633750-B1 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | EISAI R&D MAN CO LTD (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-1633750-B1 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | EISAI R&D MAN CO LTD (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20060235042-A1 | Synthesis | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1633750-A2 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | Eisai Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004078757-A2 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAIDONINES | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235042-A1 | Synthesis | AZI2, CYP3A5, CYP3A7 | FEN1 1559/4885ALOX5AP 1614/4885CDK8 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.